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Abstract
Background: Major changes in the incidence of oesophageal and gastric cancers have been reported
internationally. This study describes recent trends in incidence and survival of subgroups of oesophageal and
gastric cancer in England between 1998 and 2007 and considers the implications for cancer services and policy.
Methods: Data on 133,804 English patients diagnosed with oesophageal and gastric cancer between 1998 and
2007 were extracted from the National Cancer Data Repository. Using information on anatomical site and tumour
morphology, data were divided into six groups; upper and middle oesophagus, lower oesophagus, oesophagus
with an unspecified anatomical site, cardia, non-cardia stomach, and stomach with an unspecified anatomical site.
Age-standardised incidence rates (per 100,000 European standard population) were calculated for each group by
year of diagnosis and by socioeconomic deprivation. Survival was estimated using the Kaplan-Meier method.
Results: The majority of oesophageal cancers were in the lower third of the oesophagus (58%). Stomach with an
unspecified anatomical site was the largest gastric cancer group (53%). The incidence of lower oesophageal cancer
increased between 1998 and 2002 and remained stable thereafter. The incidence of cancer of the cardia, non-
cardia stomach, and stomach with an unspecified anatomical site declined over the 10 year period. Both lower
oesophageal and cardia cancers had a much higher incidence in males compared with females (M:F 4:1). The
incidence was also higher in the most deprived quintiles for all six cancer groups. Survival was poor in all sub-
groups with 1 year survival ranging from 14.8-40.8% and 5 year survival ranging from 3.7-15.6%.
Conclusions: An increased focus on prevention and early diagnosis, especially in deprived areas and in males, is
required to improve outcomes for these cancers. Improved recording of tumour site, stage and morphology and
the evaluation of focused early diagnosis programmes are also needed. The poor long-term survival reinforces the
need for early detection and multidisciplinary care.
Background
In 2007, oesophageal cancer was the seventh most com-
mon cancer in England in males and the fourteenth in
females, with age-standardised incidence rates (per
100,000 European standard population) of around 14.0
and 5.3, respectively [1]. Despite the declining trend in
the incidence of stomach cancer in developed countries
over the last century it was still the eighth most
common cancer in England in males and the sixteenth
in females in 2007 [1]. The population mortality rates
from oesophageal and stomach cancer closely reflect the
population incidence because of the poor prognosis of
these cancers.
Over the last 30 years the incidence of adenocarci-
noma of the oesophagus (primarily located in the lower
third) and cancers of the gastric cardia have been
increasing in many developed countries, particularly in
males [2-12]. A US study in 1991 found that the annual
increase of oesophageal adenocarcinoma in males was
greater than any other malignancy in that population
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[3]. The fact that the increase in incidence has been pre-
dominately in males suggests that the rising trends in
these cancers cannot fully be explained by changing
classifications of the diseases or improvements in diag-
nosis [7,8]. Both adenocarcinoma of the oesophagus and
cancer of the gastric cardia are typically characterised by
high male to female ratios, with the incidence in males
often being reported as up to four times higher than
that of females [3,5,6]. Internationally, the highest inci-
dence of oesophageal adenocarcinoma has been reported
in the United Kingdom [13].
Recent national studies have described the incidence
and survival of oesophageal and stomach cancer [14-16],
but have not explored specific subgroups of these can-
cers. This study aims to describe the incidence and sur-
vival of patients with oesophagogastric cancers in
England using a recent national cohort of patients diag-
nosed between 1998 and 2007.
Methods
Data on 133,804 patients (85,361 males; 48,443 females)
diagnosed with oesophageal and gastric (OG) cancer in
England between 1998 and 2007 were extracted from
the National Cancer Data Repository (NCDR). The
NCDR contains information collected by the eight Eng-
lish cancer registries on all cancer patients diagnosed in
their respective catchment areas. These data are vali-
dated and quality assured in each registry before being
combined into the English dataset.
These data are divided into six groups: 1) upper and
middle oesophagus, 2) lower oesophagus, 3) oesopha-
gus with unspecified anatomical site (from now on
referred to as oesophagus not otherwise specified
(NOS)), 4) cardia, 5) non-cardia stomach, and 6) sto-
mach with unspecified anatomical site (from now on
referred to as stomach not otherwise specified (NOS)).
These groups were defined primarily on the basis of
ICD10 (International Classification of Diseases version
10) codes (see Table 1). However, as the majority of
oesophageal adenocarcinoma is found in the lower
third of the oesophagus [7,17] while squamous cell
carcinoma is more commonly found in the upper and
middle oesophagus [17], some patients with an oeso-
phageal NOS cancer were assigned to the upper and
middle or lower oesophageal subgroups based on their
histological diagnosis.
For each cancer group age specific incidence rates
were calculated in 5 year age groups ranging from 0-4
through to 85 and over for males and females. Age-stan-
dardised incidence rates (per 100,000 European standard
population, ASR(E)) were calculated for each of the six
cancer groups by year of diagnosis and sex. ASR(E)
were also calculated by socioeconomic deprivation quin-
tile for patients diagnosed between 2003 and 2007. Post-
codes were used to assign each patient to a lower super
output area (LSOA) of residence–(LSOA are areas
including around 1,500 people). Deprivation quintiles
were assigned based on these LSOAs using the income
domain of the Indices of Deprivation 2007 [18]. Male to
female incidence rate ratios were calculated for each
group and year of diagnosis.
Survival was estimated using the Kaplan-Meier
method for each of the six patient groups. Survival was
based on patients diagnosed between 1998 and 2007
and followed up until the end of 2007. 4,990 (3.7%) of
the 133,804 patients were death certificate only registra-
tions and were excluded from the survival analysis as
they had no relevant date of diagnosis, leaving 128,814
patients. The total person time of follow-up was 142,187
years.
Table 1 Oesophago-gastric cancer group definitions
Oesophago-gastric cancer
groups
International Classification of Diseases version 10 (ICD10) and International Classification of Diseases for
Oncology (ICDO2) codes
Upper and middle
oesophagus
C15.0-C15.1, C15.3-C15.4
including C15.8-C15.9 with a morphology code
8050-8083 (Squamous cell carcinomas)
Lower oesophagus C15.2, C15.5
including C15.8-C15.9 with a morphology code
8140-8576 (Adenocarcinomas)
Oesophagus not otherwise
specified
C15.8-C15.9
excluding C15.8-C15.9 with a morphology code
8050-8083 (Squamous cell carcinomas) or
8140-8576 (Adenocarcinomas)
Cardia C16.0
Non-cardia C16.1-C16.6
Stomach not otherwise
specified
C16.8-C16.9
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A sensitivity analysis was also carried out. Oesopha-
geal cancer patients were assigned to one of three mor-
phological groups; adenocarcinoma, squamous cell
carcinoma and “other and unspecified types.” The inci-
dence and survival analyses were repeated for these
three groups.
Cancer registries in England have approval from the
National Information Governance Board to carry out
surveillance using the data they collect on all cancer
patients under section 251 of the NHS Act 2006. There-
fore separate ethical approval was not required for this
study.
Results
Upper and middle oesophageal cancer
Over half of upper and middle oesophageal cancers were
in females (Table 2). The median age at diagnosis was
73 years. Incidence remained constant over time and
was similar in males and females (Figures 1, and 2).
Incidence was higher in more deprived areas, especially
in males where the ratio between the most deprived
(quintile 5 (Q5)) and the most affluent (quintile 1 (Q1))
groups was 2.2:1 males and 1.7:1 females (Figure 3). The
age specific incidence rates were similar in males and
females (Figure 4). 30.3% [95% confidence interval 29.6-
Table 2 Characteristics of patients diagnosed with oesophago-gastric cancers in England between 1998 and 2007
Upper and
middle
oesophagus
Lower
oesophagus
Oesophagus not
otherwise
specified
Cardia Non-cardia Stomach not
otherwise
specified
Oesophageal
and gastric
cancer
18,128 35,849 7,898 18,728 15,340 37,861 133,804
Male 8,228 (45.4) 26,495 (73.9) 4,323 (54.7) 14,107 (75.3) 9,531 (62.1) 22,677 (59.9) 85,361 (63.8)
Female 9,900 (54.6) 9,354 (26.1) 3,575 (45.3) 4,621 (24.7) 5,809 (37.9) 15,184 (40.1) 48,443 (36.2)
Death certificate only (DCO) 63 (0.3) 98 (0.3) 1,769 (22.4) 117 (0.6) 51 (0.3) 2,892 (7.6) 4,990 (3.7)
Median age 73 72 78 71 75 76 74
< 50 706 (3.9) 1,682 (4.7) 180 (2.3) 1,043 (5.6) 595 (3.9) 1,568 (4.1) 5,774 (4.3)
50-54 937 (5.2) 1,986 (5.5) 227 (2.9) 1,025 (5.5) 384 (2.5) 961 (2.5) 5,520 (4.1)
55-59 1,513 (8.3) 3,149 (8.8) 396 (5.0) 1,626 (8.7) 699 (4.6) 1,671 (4.4) 9,054 (6.8)
60-64 1,864 (10.3) 3,980 (11.1) 552 (7.0) 2,124 (11.3) 1,196 (7.8) 2,646 (7.0) 12,362 (9.2)
65-69 2,320 (12.8) 4,775 (13.3) 707 (9.0) 2,680 (14.3) 2,010 (13.1) 4,326 (11.4) 16,818 (12.6)
70-74 2,851 (15.7) 5,687 (15.9) 1,030 (13.0) 3,162 (16.9) 2,735 (17.8) 6,013 (15.9) 21,478 (16.1)
75-79 3,018 (16.6) 6,170 (17.2) 1,444 (18.3) 3,185 (17.0) 3,056 (19.9) 7,293 (19.3) 24,166 (18.1)
80-84 2,496 (13.8) 4,735 (13.2) 1,364 (17.3) 2,218 (11.8) 2,497 (16.3) 6,585 (17.4) 19,895 (14.9)
85+ 2,423 (13.4) 3,685 (10.3) 1,998 (25.3) 1,665 (8.9) 2,168 (14.1) 6,798 (18.0) 18,737 (14.0)
Quintile of deprivation 2007†
1 = (Affluent) 1,503 (16.1) 3,589 (18.8) 592 (16.6) 1,554 (17.5) 1,058 (15.0) 2,607 (15.3) 10,903 (16.8)
2 1,793 (19.2) 4,133 (21.6) 701 (19.7) 1,855 (20.9) 1,320 (18.7) 3,094 (18.1) 12,896 (19.8)
3 1,980 (21.2) 4,143 (21.7) 741 (20.8) 1,941 (21.8) 1,503 (21.3) 3,409 (20.0) 13,717 (21.1)
4 1,994 (21.4) 4,000 (20.9) 791 (22.2) 1,811 (20.4) 1,625 (23.0) 3,782 (22.2) 14,003 (21.5)
5 = (Deprived) 2,058 (22.1) 3,256 (17.0) 738 (20.7) 1,730 (19.5) 1,561 (22.1) 4,180 (24.5) 13,523 (20.8)
Year of diagnosis
1998 1,702 (9.4) 3,067 (8.6) 929 (11.8) 2,022 (10.8) 1,752 (11.4) 4,446 (11.7) 13,918 (10.4)
1999 1,754 (9.7) 3,191 (8.9) 905 (11.5) 2,020 (10.8) 1,546 (10.1) 4,301 (11.4) 13,717 (10.3)
2000 1,805 (10.0) 3,292 (9.2) 923 (11.7) 2,014 (10.8) 1,669 (10.9) 4,261 (11.3) 13,964 (10.4)
2001 1,751 (9.7) 3,574 (10.0) 810 (10.3) 1,854 (9.9) 1,679 (10.9) 3,959 (10.5) 13,627 (10.2)
2002 1,788 (9.9) 3,604 (10.1) 768 (9.7) 1,927 (10.3) 1,627 (10.6) 3,822 (10.1) 13,536 (10.1)
2003 1,861 (10.3) 3,678 (10.3) 745 (9.4) 1,827 (9.8) 1,565 (10.2) 3,538 (9.3) 13,214 (9.9)
2004 1,793 (9.9) 3,732 (10.4) 717 (9.1) 1,777 (9.5) 1,472 (9.6) 3,514 (9.3) 13,005 (9.7)
2005 1,920 (10.6) 3,813 (10.6) 730 (9.2) 1,820 (9.7) 1,375 (9.0) 3,390 (9.0) 13,048 (9.8)
2006 1,871 (10.3) 3,887 (10.8) 722 (9.1) 1,740 (9.3) 1,369 (8.9) 3,264 (8.6) 12,853 (9.6)
2007 1,883 (10.4) 4,011 (11.2) 649 (8.2) 1,727 (9.2) 1,286 (8.4) 3,366 (8.9) 12,922 (9.7)
†Based on patients diagnosed between 2003 and 2007.
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31.0%] of patients survived 1 year and 8.3% [7.8-8.7%]
survived five years after diagnosis (Figure 5). The results
for the oesophageal squamous cell carcinoma group
were similar to the upper and middle oesophageal can-
cer group.
Lower oesophageal cancer
The majority of oesophageal cancers were located in the
lower oesophagus, and almost three quarters were in
males (Table 2). The median age at diagnosis was 72
and the number of cases increased over the period.
Lower oesophageal cancer in males had the highest inci-
dence of all the oesophageal groups. The incidence rose
from 8.1 per 100,000 in 1998 to 10.1 in 2007 and was
relatively stable after 2002 (Figure 1). The difference in
incidence between males and females was most evident
in this subgroup (M:F 4:1) and incidence was higher in
more deprived areas (Q5:Q1 1.2:1 males; 1.3:1 females)
(Figures 2, and 3). 36.4% [35.9-36.8%] of patients sur-
vived 1 year and 9.4% [9.1-9.8%] survived 5 years after
diagnosis (Figure 5). The results for the oesophageal
adenocarcinoma group were similar to the lower oeso-
phageal cancer group.
Oesophageal NOS
A small proportion of oesophageal cancer patients had
NOS disease and the median age at diagnosis was 78
(Table 2). The incidence decreased over the period, and
was higher in males than females, and in more deprived
areas (Figures 1, 2, and 3). 14.8% [13.9-15.7%] of
patients survived 1 year and 3.7% [3.2-4.3%] survived 5
years after diagnosis (Figure 5). The results for the oeso-
phageal other and unspecified morphology group were
similar to the oesophageal NOS cancer group.
Cardia
Over three quarters of cardia cancers were in males
(Table 2). The median age at diagnosis was 71. Inci-
dence declined slightly over the period falling from 5.7
to 4.2 per 100,000 in males and from 1.4 to 1.1 in
females (Figure 1). Like lower oesophageal cancer the
incidence of cardia cancer was much higher in males
than females (M:F 4:1) and was higher in the most
deprived quintiles (Q5:Q1 1.5:1 males; 1.7:1 females)
(Figures 2, and 3). 40.0% [39.3-40.7%] of patients sur-
vived 1 year and 10.9% [10.4-11.4%] survived 5 years
after diagnosis (Figure 5).
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Non-cardia
Sixty-two per cent of non-cardia stomach cancers were
in males (Table 2). The median age at diagnosis was 75
and the annual number of cases declined over time.
Incidence also declined, was twice as high in males, and
was higher in more deprived areas (Q5:Q1 2.0:1 males;
1.9:1 females) (Figures 1, 2 and 3). 40.8% [40.0-41.6%] of
patients survived 1 year and 15.6% [15.0-16.3%] survived
5 years after diagnosis (Figure 5).
Stomach NOS
Over half of stomach cancers were NOS (Table 2). The
median age at diagnosis was 76. The incidence fell from
9.4 per 100,000 in 1998 to 6.3 in 2007 in males and
from 4.2 to 3.0 in females (Figure 1). Incidence was
higher in males (M:F 2:1), in the more deprived groups
(Q5:Q1 2.1:1 in both sexes), and was particularly high in
the oldest age groups (Figure 2, 3, and 4). 28.5% [28.0-
29.0%] of patients survived 1 year and 10.1% [9.8-10.5%]
survived 5 years after diagnosis (Figure 5).
Discussion
This study investigated the incidence and survival of
oesophageal and gastric cancers in England using data
on 133,804 patients diagnosed between 1998 and 2007.
The incidence of lower oesophageal cancer increased
until 2002 then remained relatively stable, whereas the
incidence of cancers of the cardia, non-cardia, and sto-
mach NOS declined over this period. The incidence was
higher in males compared with females for both oeso-
phageal and gastric cancer. This was most evident in
lower oesophageal and cardia cancers where the inci-
dence was around four times higher in males. In general
the incidence rates of all oesophageal and gastric can-
cers were higher in the more deprived areas. Overall
survival was poor in all sub-groups with 1 year survival
ranging from 14.8 to 40.8% and 5 year survival ranging
from 3.7 to 15.6%.
Strengths and limitations
This national study included a large number of patients
diagnosed with oesophageal or stomach cancer over a
10 year period. It was therefore possible to investigate
differences in incidence by six cancer subgroups rather
than only the traditional groups of oesophageal (C15)
and stomach (C16) cancer, which obscure the unique
features of the lower oesophageal and cardia tumours. It
is also strengthened by available socioeconomic and sur-
vival data.
One limitation of the dataset was the relatively large
proportion of patients with an unspecified anatomical
subsite, particularly for gastric cancers where over half
(52.6%) fell into this group. This meant that these
patients could not be assigned to either the cardia or
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non-cardia subgroup. Defining the oesophageal cancer
groups using both the anatomical site and tumour mor-
phology led to a smaller proportion of patients in the
not otherwise specified group (12.8%) compared to the
groups defined and used for the sensitivity analysis
based on morphology alone (17.5%). This sensitivity
analysis demonstrated similar patterns in incidence and
survival between the oesophageal squamous cell carci-
noma group and the upper and middle oesophageal
group, the oesophageal adenocarcinoma group and the
lower oesophageal group, and the “other and unspeci-
fied” and the oesophageal not otherwise specified group.
Finally, another limitation was that 4,990 patients (4%)
had to be excluded from the survival analysis as their
registrations were based only on data from the death
certificate.
Comparison to previous studies
In most developed countries the incidence of oesopha-
geal squamous cell carcinoma, which is more commonly
found in the upper and middle oesophagus [17], has
remained constant or declined over the last 30 years [11]
whilst the incidence of oesophageal adenocarcinoma,
primarily found in the lower third of the oesophagus
[7,17] has increased, particularly in males [2-12]. In Swe-
den the increase in oesophageal adenocarcinoma inci-
dence peaked in the mid 2000’s and then remained stable
[19]. Our study found similar results with stable inci-
dence rates of upper and middle oesophageal cancer over
the 10 year period and an initial increase in the incidence
of lower oesophageal cancer in males which has slowed
and remained relatively stable after 2002.
The increase in the incidence of lower oesophageal
cancer is mirrored in our study by a decrease in the
incidence of cancers of the cardia. Previous studies have
noted an increase in both these cancer groups [2-8],
although others have found a similar stable or slightly
declining trend in the incidence of gastric cardia cancer
since the early 1990’s [2,12,19]. It is possible that the
trends in these two adjacent sites were influenced by
changing diagnostic classification. However, after 2002
when the incidence of lower oesophageal cancer
remained stable in males the incidence of cardia cancer
continued to decline. If changes in diagnostic classifica-
tion were responsible these trends would be expected to
stabilise at a similar time. It is also possible that some of
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the oesophageal NOS cancers could have been cardia
cancers. Reassigning those with a histological diagnosis
of adenocarcinoma to the lower oesophageal group may
have influenced the trends. A decline in the incidence of
non-cardia gastric cancer in more developed countries
has been seen in the past century [8,20-22]. Our study
confirms this continued decline for both non-cardia sto-
mach and stomach NOS cancers.
The declining incidence of gastric cancers in this
study and other studies [8,20-22] may be associated
with the decreasing prevalence in developed countries of
Helicobacter pylori infection, a known risk factor for
gastric cancer [20]. However, meta-analyses have found
that infection with the most common H pylori strains
(CagA+) may protect against the development of oeso-
phageal adenocarcinoma, possibly because infection
causes achlorhydria and so reduces gastric acid reflux,
one of the main risk factors associated with the develop-
ment of oesophageal adenocarcinoma [23,24]. A sys-
tematic review did find a lower prevalence of H pylori
infection in patients with gastro-oesophageal reflux dis-
ease (GORD) [25]. Therefore, the declining prevalence
of H pylori infection could contribute to the increasing
incidence of lower oesophageal cancer found here.
The increasing incidence of oesophageal adenocarci-
noma found in this study may also be associated with
the rising prevalence of obesity in England [26]. Other
studies have found that increasing body mass index is
associated with an increased risk of oesophageal adeno-
carcinoma and cardia cancer [27,28].
Consistent with previous studies [3-8,12] lower oeso-
phageal and cardia cancer incidence rates were much
higher in males compared with females (M:F 4:1). The
reasons for this is not clear, but an abdominal distribu-
tion of body fat, which is more common in males, may
lead to higher levels of GORD and therefore to an
increased risk of developing these cancers [27,29]. Bar-
rett ’s oesophagus, secondary to chronic GORD, is
another risk factor which occurs more commonly in
males [30] and has been linked to abdominal obesity
[27,31]. Differing patterns of past smoking behaviours
in males and females could also partly explain the dif-
fering incidence of these cancers. The risk of develop-
ing squamous cell carcinoma of the oesophagus
declines steadily following smoking cessation, although
the risk of both oesophageal adenocarcinoma and car-
dia cancer does not decline until 30 years after cessa-
tion [32].
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The finding that lower oesophageal and cardia cancer
have a higher incidence in the more socioeconomically
deprived groups contradicts other studies which have
found no association [9]. Squamous cell carcinoma [9]
and gastric cancer [20] have been associated with depri-
vation in previous studies, which our findings support.
The known lifestyle risk factors already discussed are
likely to be more common in those living in deprived
areas and so explain the higher incidence found in our
study.
Implications for policy and practice
The poor prognosis of both oesophageal and gastric
cancer highlights the need to concentrate efforts on pri-
mary prevention. Smoking and high alcohol consump-
tion are risk factors for gastric cancer and squamous
cell carcinoma of the oesophagus [33-35]. Smoking is
also a risk factor for oesophageal adenocarcinoma, but
the role of alcohol consumption is less certain [34].
Public health initiatives aimed at reducing smoking and
encouraging sensible alcohol consumption would help
reduce the incidence of these cancers. A systematic
review found that reducing weight may improve symp-
toms of GORD although not all studies have found this
association [27]. Other public health initiatives aimed at
reducing obesity therefore may help to decrease the pre-
valence of chronic GORD which is one of the main risk
factors for developing oesophageal adenocarcinoma.
The particularly high incidence of lower oesophageal
and cardia tumours in males may have implications for
earlier diagnosis. Current guidelines for referral and
investigation of upper gastrointestinal symptoms do not
specify this increased risk in males, but advise a similar
threshold for males and females [36]. Raising awareness
in primary care of the differing incidence should be con-
sidered, and a lower threshold for referral in males
investigated. The poor prognosis of all patients suggests
that evaluation of a national programme of earlier
Number at risk 0 1 2 3 4 5
Non-cardia 15,289    5,686    3,353    2,336    1,715    1,260    
Cardia 18,611    6,709    3,276    2,035    1,386    970    
Stomach NOS 34,969    8,972    4,950    3,368    2,458    1,849    
Lower oesophagus 35,751    11,415    5,157    3,047    2,037    1,389    
Upper and middle oesophagus 18,065    4,856    2,175    1,328    925    674    
Oesophagus NOS 6,129    815    340    215    158    115    
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Figure 5 Kaplan-Meier survival functions for oesophago-gastric cancers diagnosed in England between 1998 and 2007. Followed up to
the end of December 2007.
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investigation of non-specific UGI symptoms may be
warranted, and new tools such as the cytosponge for
identifying Barretts’ epithelium may have a role to play
in the future [33,37].
Since oesophageal and gastric tumours are relatively
uncommon and difficult to diagnose population-wide
screening is unlikely to be cost effective. Efforts to iden-
tify high risk groups such as those with regular chronic
reflux (oesophageal cancer) could perhaps be considered
in developing focused screening efforts in the future,
but evidence on the effectiveness of screening these
groups will be needed. At present endoscopic screening
is not considered feasible [33]. However, an American
study in 2010 did suggest that the incidence in White
males over 60 with weekly GORD or over 55 with daily
GORD was high enough to investigate the effectiveness
of screening in these groups [38].
The poor prognosis of these cancers also suggests the
need for greater focus on earlier diagnosis. Raising pub-
lic awareness and knowledge of symptoms, particularly
in more deprived areas and in males, will be important.
A recent study found that 21% of oesophageal and 32%
of stomach cancers were diagnosed as a result of emer-
gency admissions and that emergency admissions were
associated with poorer one-year survival [39]. Therefore,
greater awareness of these cancers and improved knowl-
edge of symptoms could help to identify earlier stage
tumours and consequently improve the prognosis of
these cancers.
Unanswered questions and future research
These data highlight the need for further aetiological
research to understand the links between sex and oeso-
phageal and gastric cancers. Of particular importance is
to fully understand why the incidence rates of lower
oesophageal and cardia cancer are so much higher in
males compared with females, why the incidence of these
cancers are higher in the UK compared with other devel-
oped countries and why the incidence has increased over
time. This study lacked information on several factors
that may affect the incidence of these cancers such as
smoking, alcohol, obesity, GORD and H pylori infection
which, if available, could have helped in the interpreta-
tion of the analysis. Future work could record how these
factors vary within populations in England. An earlier
English study found significantly higher postoperative
mortality following operations for oesophageal cancer in
patients living in more deprived areas [40]. Future studies
could also investigate differences in survival for the six
subgroups in this study taking into account other factors
that influence survival such as age, socioeconomic depri-
vation and stage of disease.
Finally, these data also show that better classification
of gastric tumours by site is needed to understand
outcomes. It is important that both the cancer site and
the morphology of these cancers are identified and
recorded in clinical practice where possible. This infor-
mation needs to be passed to the cancer registries to
ensure that further studies can investigate these groups
with more accuracy.
Conclusion
In England, the incidence of lower oesophageal cancer
in males increased until 2002 then remained relatively
stable, whereas the incidence of cardia and non-cardia
gastric cancers declined between 1998 and 2007. Can-
cers of the lower oesophagus and cardia were more
likely to occur in males than females and the incidence
for all oesophageal and gastric cancer subgroups was
higher in more deprived areas. The prognosis for these
cancers remains very poor. An increased focus on pre-
vention and early diagnosis, especially in deprived areas
and in males, is required to improve outcomes for oeso-
phageal and gastric cancers. Improved recording of
tumour site, stage and morphology and the evaluation
of focused early diagnosis programmes are also needed.
The poor survival reinforces the need for early detection
and multidisciplinary care.
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